Why Centene Stock Dropped 40% — And Whether It's a Buy Now

Centene shares plummeted over 40% on July 2nd, erasing $11 billion in market capitalization, after the company withdrew its 2025 guidance due to updated ACA exchange market data indicating lower enrollment growth and higher patient morbidity, projecting a significant $2.75 hit to its diluted EPS. This sell-off also impacted competitors like Molina Healthcare and Elevance Health. Further exacerbating the outlook, the recently signed "One Big Beautiful Bill" includes $1 trillion in Medicaid cuts over the next decade, a segment representing 46% of Centene's revenue, introducing substantial new risk and uncertainty for Centene and its peers despite some analysts perceiving an improved valuation post-decline.

Analysis

Centene (CNC) experienced a catastrophic single-day valuation reset, with its shares falling over 40% on July 2 after withdrawing its 2025 full-year guidance. This erased over $11 billion in market capitalization and created significant contagion, dragging down peers Molina Healthcare (MOH) by 22% and Elevance Health (ELV) by over 11%. The withdrawal was triggered by third-party data revealing a fundamental deterioration in the Affordable Care Act (ACA) exchange market, characterized by lower-than-expected enrollment growth and higher patient morbidity. This adverse combination is projected to reduce Centene's 2025 diluted EPS by $2.75, a 38% hit to its previous forecast. Compounding this operational headwind is a severe new legislative risk from the "One Big Beautiful Bill," signed into law on July 4. This bill mandates $1 trillion in Medicaid cuts over a decade, directly threatening Centene's largest revenue stream, which accounted for 46% of its total revenue last quarter. While some post-decline analyst targets suggest a 53% upside to a revised average of $51, these forecasts were made before the Medicaid legislation was signed, rendering them potentially obsolete. The combination of a structurally weaker ACA market and a major blow to its core Medicaid business introduces a highly elevated and unquantified risk profile for the company.

Key Decisions for Investors

• Investors should exercise extreme caution, as the 40% stock decline may not fully price in the dual headwinds from both the deteriorating ACA market fundamentals and the newly enacted $1 trillion in Medicaid cuts.
• Closely monitor upcoming company disclosures and management commentary for specific quantification of the financial impact from the Medicaid legislation, as this now represents the most significant long-term risk to Centene's revenue base.
• Treat current analyst price targets with skepticism, as even recently revised targets likely fail to incorporate the material impact of the Medicaid cuts signed into law after their publication.
• A sideline position is prudent until there is greater clarity on the combined earnings impact from both the ACA and Medicaid challenges, as visibility into the company's future financial performance is exceptionally low.